ECSP24008488A - Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer - Google Patents

Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer

Info

Publication number
ECSP24008488A
ECSP24008488A ECSENADI20248488A ECDI202408488A ECSP24008488A EC SP24008488 A ECSP24008488 A EC SP24008488A EC SENADI20248488 A ECSENADI20248488 A EC SENADI20248488A EC DI202408488 A ECDI202408488 A EC DI202408488A EC SP24008488 A ECSP24008488 A EC SP24008488A
Authority
EC
Ecuador
Prior art keywords
pi3k
inhibit
methods
compounds
alpha isoform
Prior art date
Application number
ECSENADI20248488A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP24008488A publication Critical patent/ECSP24008488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta descripción proporciona compuestos de la Fórmula (I) y sales farmacéuticamente aceptables de estos, que inhiben la isoforma alfa (PI3Kα) de la fosfatidilinositol 4,5-bisfosfato 3-quinasa (PI3K). Estas entidades químicas son útiles, por ejemplo, para tratar una afección, enfermedad o trastorno en el que el aumento (por ejemplo, excesivo) de la activación de PI3Kα contribuye a la patología y/o a los síntomas y/o a la progresión de la afección, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano). Esta descripción también proporciona composiciones que contienen la misma, así como también métodos de uso y fabricación de la misma.
ECSENADI20248488A 2021-08-09 2024-02-01 Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer ECSP24008488A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163231156P 2021-08-09 2021-08-09

Publications (1)

Publication Number Publication Date
ECSP24008488A true ECSP24008488A (es) 2024-05-31

Family

ID=83188497

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20248488A ECSP24008488A (es) 2021-08-09 2024-02-01 Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer

Country Status (20)

Country Link
US (1) US20240343728A1 (es)
EP (1) EP4363414A1 (es)
JP (1) JP2024533975A (es)
KR (1) KR20240051953A (es)
CN (1) CN118159534A (es)
AU (1) AU2022325819A1 (es)
CA (1) CA3227902A1 (es)
CL (1) CL2024000327A1 (es)
CO (1) CO2024000448A2 (es)
CR (1) CR20240045A (es)
DO (1) DOP2024000019A (es)
EC (1) ECSP24008488A (es)
GE (1) GEAP202416449A (es)
IL (1) IL310588A (es)
JO (1) JOP20240020A1 (es)
MA (1) MA63885B1 (es)
MX (1) MX2024000708A (es)
PE (1) PE20240652A1 (es)
WO (1) WO2023018636A1 (es)
ZA (1) ZA202401094B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097721A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
WO2025036439A1 (en) * 2023-08-16 2025-02-20 Laekna Pharmaceutical Ningbo Co., Ltd. Multicyclic compounds and their use as pi3k alpha inhibitors
WO2025144931A1 (en) * 2023-12-27 2025-07-03 Genesis Therapeutics, Inc. Methods for treating cancer
WO2025201503A1 (en) * 2024-03-28 2025-10-02 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
UA99469C2 (ru) * 2007-06-26 2012-08-27 Юсиби Фарма, С.А. Конденсированные производные тиазола как ингибиторы киназы
CA2755285C (en) * 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
DE102009043260A1 (de) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
WO2011163195A1 (en) * 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
SG11201610770PA (en) * 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
TWI649326B (zh) * 2015-07-02 2019-02-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其製備方法
WO2017221272A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Process for the preparation of idelalisib
WO2021001431A1 (en) * 2019-07-02 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer

Also Published As

Publication number Publication date
JOP20240020A1 (ar) 2024-02-01
CA3227902A1 (en) 2023-02-16
JP2024533975A (ja) 2024-09-18
PE20240652A1 (es) 2024-04-04
MA63885B1 (fr) 2025-01-31
DOP2024000019A (es) 2024-03-15
CR20240045A (es) 2024-02-20
CN118159534A (zh) 2024-06-07
IL310588A (en) 2024-04-01
CO2024000448A2 (es) 2024-02-15
US20240343728A1 (en) 2024-10-17
AU2022325819A1 (en) 2024-02-29
ZA202401094B (en) 2025-05-28
EP4363414A1 (en) 2024-05-08
MX2024000708A (es) 2024-02-08
GEAP202416449A (en) 2024-04-25
CL2024000327A1 (es) 2024-08-09
MA63885A1 (fr) 2024-09-30
KR20240051953A (ko) 2024-04-22
WO2023018636A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
DOP2023000271A (es) Derivados de la urea que pueden ser utilizados para tratar el cáncer
CO2024000448A2 (es) Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
ECSP13012752A (es) Imidazopiridazinas sustituidas
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
MX2022014924A (es) Moduladores de il-17a.
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CL2025002448A1 (es) Compuestos inhibidores de quinasa dependientes de ciclina (cdk2).
CO2022014886A2 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
MX2025004073A (es) Métodos para tratar el cáncer
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones
UY39819A (es) Métodos para tratar el cáncer
MX2025004911A (es) Terapia de combinacion para tratar el cancer
AR126147A1 (es) Derivados de urea para tratar el cáncer
MX2021008748A (es) Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR123760A1 (es) Métodos para tratar el cáncer
AR123576A1 (es) Métodos para tratar el cáncer